Literature DB >> 24333861

First case of drug rash eosinophilia and systemic symptoms due to boceprevir.

Agnès Samain1, Anne-Bénédicte Duval-Modeste2, Pascal Joly2, Céline Leblanc2, Nathalie Massy3, Philippe Courville4, Odile Goria5, Ghassan Riachi5.   

Abstract

Boceprevir and telaprevir are 2 specific inhibitors of the hepatitis C (HCV) serine protease 3. Cutaneous side effects have been reported with high frequency, essentially rash, and dry skin. We report a case of drug rash with eosinophilia and systemic symptoms (DRESS) due to boceprevir. A 56-year-old African woman with chronic hepatitis C complicated with cirrhosis and cryoglobulinemia received pegylated interferon alfa-2a (PegIFN) and ribavirin (RBV) for 4 weeks and then boceprevir was added. She was also co-infected with HIV state A2. Eight weeks after adding boceprevir she developed a generalized maculopapular exanthema with fever, facial oedema, apparition of lymph node and alteration of the general state. She presented an eosinophilia (up to 3.0 × 10(9)cells/L), no biological inflammatory syndrome. The computed tomography revealed several lymph nodes located in the abdominal and inguinal areas. The cutaneous biopsy was consistent with a drug rash reaction. The HCV treatment was stopped and the patient was treated with topical steroids. Cutaneous and systemic symptoms disappeared in few weeks. Boceprevir was considered the culprit drug. We report to our knowledge the first case of DRESS due to boceprevir.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Boceprevir; Drug rash eosinophilia and systemic symptoms; Hepatitis C

Mesh:

Substances:

Year:  2013        PMID: 24333861     DOI: 10.1016/j.jhep.2013.12.008

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  4 in total

1.  Ticagrelor-induced pneumonitis and subsequent pulmonary hemorrhage; drug rash with eosinophilia due to boceprevir; hepatitis C reactivation after starting infliximab; hydralazine-associated immune glomerulonephritis; fluoroquinolones and retinal detachment.

Authors:  Michael A Mancano
Journal:  Hosp Pharm       Date:  2014-06

2.  Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C.

Authors:  Elżbieta Kłujszo; Piotr Parcheta; Dorota Zarębska-Michaluk; Ewa Ochwanowska; Anna Witkowska; Adriana Rakowska; Lidia Rudnicka; Wiesław Kryczka
Journal:  J Dermatol Case Rep       Date:  2014-12-31

Review 3.  Antiviral drug allergy.

Authors:  Brigitte Milpied-Homsi; Ellen M Moran; Elizabeth J Phillips
Journal:  Immunol Allergy Clin North Am       Date:  2014-08       Impact factor: 3.479

Review 4.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System.

Authors:  Yung-Tsu Cho; Che-Wen Yang; Chia-Yu Chu
Journal:  Int J Mol Sci       Date:  2017-06-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.